» Articles » PMID: 18777597

Maintenance Time of Sedative Effects After an Intravenous Infusion of Diazepam: a Guide for Endoscopy Using Diazepam

Overview
Specialty Gastroenterology
Date 2008 Sep 9
PMID 18777597
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

Aim: To examine whether the sedative effects assessed by psychomotor tests would depend on the cytochrome P450 (CYP) 2C19 genotypes after an infusion regimen of diazepam commonly used for gastrointestinal endoscopy in Japan.

Methods: Fifteen healthy Japanese volunteers consisting of three different CYP2C19 genotype groups underwent a critical flicker fusion test, an eye movement analysis and a postural sway test as a test for physical sedative effects, and a visual analog scale (VAS) symptom assessment method as a test for mental sedative effects during the 336 h period after the intravenous infusion of diazepam (5 mg).

Results: The physical sedative effects assessed by the critical flicker test continued for 1 h (t values of 5 min, 30 min and 60 min later: 4.35, 5.00 and 3.19, respectively) and those by the moving radial area of a postural sway test continued for 3 h (t values of 5 h, 30 h, 60 min and 3 h later: -4.05, -3.42, -2.17 and -2.58, respectively), which changed significantly compared with the baseline level before infusion (P<0.05). On the other hand, the mental sedative effects by the VAS method improved within 1 h. The CYP2C19 genotype-dependent differences in the postinfusion sedative effects were not observed in any of the four psychomotor function tests.

Conclusion: With the psychomotor tests, the objective sedative effects of diazepam continued for 1 h to 3 h irrespective of CYP2C19 genotype status and the subjective sedative symptoms improved within 1 h. Up to 3 h of clinical care appears to be required after the infusion of diazepam, although patients feel subjectively improved.

Citing Articles

Clinical Impact of the Gene on Diazepam for the Management of Alcohol Withdrawal Syndrome.

Ho T, Noble M, Tran B, Sunjic K, Varghese Gupta S, Turgeon J J Pers Med. 2023; 13(2).

PMID: 36836519 PMC: 9961427. DOI: 10.3390/jpm13020285.


Role of CYP2C19 gene polymorphism in acute alcohol withdrawal treatment with loading dose of diazepam in a South Indian population.

Jose M, Mathaiyan J, Kattimani S, Adithan S, Chandrasekaran A Eur J Clin Pharmacol. 2016; 72(7):807-12.

PMID: 27099220 DOI: 10.1007/s00228-016-2061-x.

References
1.
Kosuge K, Jun Y, Watanabe H, Kimura M, Nishimoto M, Ishizaki T . Effects of CYP3A4 inhibition by diltiazem on pharmacokinetics and dynamics of diazepam in relation to CYP2C19 genotype status. Drug Metab Dispos. 2001; 29(10):1284-9. View

2.
Herman R, Wilkinson G . Disposition of diazepam in young and elderly subjects after acute and chronic dosing. Br J Clin Pharmacol. 1996; 42(2):147-55. PMC: 2042656. DOI: 10.1046/j.1365-2125.1996.03642.x. View

3.
de Morais S, Wilkinson G, Blaisdell J, Nakamura K, Meyer U, Goldstein J . The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem. 1994; 269(22):15419-22. View

4.
Divoll M, Greenblatt D, Ochs H, Shader R . Absolute bioavailability of oral and intramuscular diazepam: effects of age and sex. Anesth Analg. 1983; 62(1):1-8. View

5.
Chang M, Dahl M, Tybring G, Gotharson E, Bertilsson L . Use of omeprazole as a probe drug for CYP2C19 phenotype in Swedish Caucasians: comparison with S-mephenytoin hydroxylation phenotype and CYP2C19 genotype. Pharmacogenetics. 1995; 5(6):358-63. DOI: 10.1097/00008571-199512000-00004. View